CSBR.OB - CHAMPIONS BIOTECHNOLOGY, INC.
2200 Wilson Blvd, Suite 102-316, Arlington, VA 22201
Primary State of Incorporation: Delaware
James Martell, Chairman/President/CEO
James E. McCollam, Secretary
On February 14, 2007, the Registrant agreed to acquire all of the patent rights underlying pending U.S. Patent Application no. 11/673,519 and corresponding international patent application (PCT/US2006/014449) filed under the Patent Cooperation Treaty (PCT), both entitled “Design and Synthesis of Novel Tubulin Polymerization Inhibitors: Benzoylphenylurea (BPU) Sulfur Analogs.” The acquisition represents the commencement of the Registrant’s strategy to develop a biotechnology business based on therapeutic drug candidates among other possible ventures.
The purchase price for the patent rights consisted of an aggregate of up to 550,000 restricted shares of common stock, of which 300,000 restricted shares were issued upon execution of the acquisition agreement and 250,000 restricted shares are issuable upon the issuance of one or patents based on U.S. Patent Application no. 11/673,519. The Registrant has 27,624,658 issued and outstanding common shares and of those, 19,573,000 are restricted common shares.
On January 5, 2007, the Registrant agreed to issue 7,000,000 shares of common stock toDr. David Sidransky, an individual investor, for an aggregate purchase price of $28,000. These securities were issued pursuant to a privately negotiated transaction without an underwriter in reliance upon the exemption from registration provided by Section 4(2) of the Securities Act.
On January 3, 2007, the Registrant agreed to issue 2,500,000 shares of common stock to Dr. Manuel Hidalgo, an individual investor, for an aggregate purchase price of $10,000. These securities were issued pursuant to a privately negotiated transaction without an underwriter in reliance upon the exemption from registration provided by Section 4(2) of the Securities Act.
David Sidransky, M.D.
David Sidransky, M.D., has served as a director of the ImClone Systems, since January 2004. On June 15, 2005, Dr. Sidransky was named Vice Chairman of the Board of Directors. Dr. Sidransky is the Director of the Head and Neck Cancer Research Division at Johns Hopkins University School of Medicine. He is a founder of several private biotechnology companies and has served on scientific advisory boards of many private and publicly traded companies, including MedImmune Inc., Telik Inc., Roche, and Amgen Inc. Dr. Sidransky is also a director of Alfacell Inc. He was formerly on the Board of Scientific Counselors at the National Institute of Dental and Craniofacial Research and a member of the Recombinant DNA Advisory Committee at the National Institute of Health. Dr. Sidransky serves on numerous editorial boards and is Senior Editor of Clinical Cancer Research. In addition, he is a Professor of Oncology, Otolaryngology-Head and Neck Surgery, Cellular & Molecular Medicine, Urology, Genetics, and Pathology at Johns Hopkins University and Hospital. Dr. Sidransky is certified in Internal Medicine and Medical Oncology by the American Board of Medicine. He has over 250 peer-reviewed publications, and has contributed more than 40 cancer reviews and chapters and also has numerous issued biotechnology patents. He has been the recipient of many awards and honors, including the 1997 Sarstedt International Prize from the German Society of Clinical Chemistry, the 1998 Alton Ochsner Award
Link to David Sidransky's patents:
Manuel Hidalgo, M.D., Ph.D.
-Associate Professor of Oncology at the Johns Hopkins Institute.
-M.D.,University Navarra Medical School, Pamplona, Spain
-Ph.D., Infectious Diseases in Cancer, Univeristy Autonoma, Madrid, Spain
-Fellowship (Medical Oncology) University Hospital “12 de Octubre”, Madrid, Spain
-Research Fellow, University Hospital “ 12 de Octubre”, Madrid, Spain
-Clinical Research Fellow, Cancer Therapy and Research Center, San Antonio, TX
-Board Certification in Medical Oncology
-Clinical Interests: Stomach cancer, Colon and rectum cancers, Pancreas cancer, Biliary Tract cancer, Gallbladder cancer.
Dr. Hidalgo is considered a leading researcher in the development of targeted therapies for the treatment of cancer in patients with solid tumors. His research focuses on optimizing the clinical development of novel treatments by measuring target receptor and molecular anomalies, as well as analyzing the biological activity in tumor and normal tissues of patients treated with specific therapies. Dr. Hidalgo is the Principal Investigator in four new clinical studies started within the last year at the Drug Development Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine.
Link to Manuel Hidalgo's patents:
OS: 31,624,658 issued and outstanding common shares
Transfer Agent: Integrity Stock Transfer, Las Vegas, NV 89120
News Items and Filings
|Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader |
BALTIMORE, Sept. 1 /PRNewswire-FirstCall/ -- Champions Biotechnology, Inc. (OTC:CSBR) (BULLETIN BOARD: CSBR) , a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
By maintaining the fundamental genotypic features of the original human tumor along with the stromal components, the Biomerk Tumorgraft preclinical platform enables identification of the most promising development path for a compound in terms of indication, drug combination, and target patient population. The platform also has the potential to identify gene pathways of response and resistance as well as prognostic molecular biomarkers.
"We are excited to continue the growth of our impressive client base and begin working with one of the most respected global leaders in the discovery and development of novel therapies," said Doug Burkett, Ph.D., President of Champions Biotechnology, Inc. "Studies suggest that evaluation of oncology compounds through our Biomerk Tumorgraft platform will lead to more successful and efficient clinical development. The value-added by an optimally targeted, more efficient clinical path can result in cost savings, improved clinical and commercial success and significantly more years of patent life following commercialization."
About Champions Biotechnology, Inc.
Champions Biotechnology, Inc. is engaged in the development of advanced preclinical platforms and tumor specific data to enhance and accelerate the value of oncology drugs. The Company's Preclinical Platform is a novel approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments (Biomerk Tumorgrafts(TM)) in a manner that preserves the biological characteristics of the original human tumor. Early studies suggest that unlike traditional xenografts, these Tumorgrafts closely reflect human cancer biology and their response to drugs is predictive of clinical outcomes in cancer patients. Champions Biotechnology leverages its preclinical platform to evaluate drug candidates and to develop a portfolio of novel therapeutic candidates. As drugs progress through early stage development, the Company plans to sell, partner or license them to pharmaceutical and/or biotechnology companies, as appropriate. The Company also offers its predictive preclinical platform and tumor specific data to physicians for personalized patient care and to companies for evaluation of oncology drugs in models that integrate prognostic testing with biomarker discovery.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ Weekly Chart Long Term Chart Daily Chart